Investment Firm
Overview
Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Nov 14, 2017
Series A
Highlights
Location
Social
Participant Investors
3
Locus Biosciences raised $19000000 on 2017-11-14 in Series A
Locus Biosciences develops CRISPR-engineered precision antibacterial platform designed to revolutionize the treatment of bacterial disease.
Company Funding History
10
Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
---|---|---|---|---|
Feb 14, 2022 | Venture Round - Locus Biosciences | - | 10.5M | |
Apr 15, 2016 | Seed Round - Locus Biosciences | - | 1.3M | |
Dec 06, 2016 | Debt Financing - Locus Biosciences | - | 350.0K | |
May 18, 2022 | Series B - Locus Biosciences | 5 | - | 35.0M |
Recent Activity
There is no recent news or activity for this profile.